Remove Clinic Remove Imaging Remove Radiopharmaceuticals Remove Workshop
article thumbnail

First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies

Imaging Technology

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use.

article thumbnail

GE HealthCare Announces New Data Validating Artificial Intelligence Models for Predicting Patient Response to Immunotherapies

Imaging Technology

2] In addition to the potential benefits of these AI models in clinical use, with roughly 5,000 immunotherapies in development today [3] , selecting patients more likely to respond could also help drug developers to speed up and increase the likelihood of success of clinical trials.